<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24525" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Biochemistry, Lupus Anticoagulant</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rasool</surname>
            <given-names>Zoaib S.</given-names>
          </name>
          <aff>Sovah</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tiwari</surname>
            <given-names>Vivekanand</given-names>
          </name>
          <aff>Dartmouth Hitchcock Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Zoaib Rasool declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vivekanand Tiwari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24525.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The term 'lupus anticoagulant' is a misnomer as it is neither only found in lupus, nor is it mainly associated with bleeding.&#x000a0;The term LA was first coined to describe the phenomenon of plasma samples from patients with systemic lupus erythematosus (SLE) that failed to clot within an appropriate time.<xref ref-type="bibr" rid="article-24525.r1">[1]</xref>&#x000a0;Lupus anticoagulant (LA) is one the of antiphospholipid antibodies, which also include anticardiolipin (aCL) antibody and anti-beta2-glycoprotein (GP) I &#x000a0;antibodies. LA are heterogenous autoantibodies, predominantly IgG, and IgM isotypes that specifically target the phospholipid-protein component of the cell membrane.&#x000a0;LA interferes and prolongs clotting process, which is a risk factor for arterial and/or venous thrombosis with complications such as stroke, transient ischemic strokes, acquired thrombophilia, and pregnancy loss.&#x000a0; Furthermore, LAs may be transitory in the setting of certain medications or infections and thus have also present in asymptomatic patients.<xref ref-type="bibr" rid="article-24525.r2">[2]</xref> Testing for LAs is essential in patients with hypercoagulable states and antiphospholipid syndromes.<xref ref-type="bibr" rid="article-24525.r3">[3]</xref></p>
      </sec>
      <sec id="article-24525.s2" sec-type="Fundamentals">
        <title>Fundamentals</title>
        <p>Lupus anticoagulants are a heterogeneous class of immunoglobulins that specifically target the epitopes of the negatively charged phospholipid binding protein of cell membrane, prothrombin, and beta2-glycoprotein I (beta2-GPI) which inhibit phospholipid-dependent coagulation in vitro.<xref ref-type="bibr" rid="article-24525.r4">[4]</xref>&#x000a0; Therefore, ironically, LA is associated with arterial and venous thrombosis rather than bleeding. Thrombotic risk due to LA is considered to be strongest compared to anti&#x02013;beta-glycoprotein I or anticardiolipin antibodies.<xref ref-type="bibr" rid="article-24525.r5">[5]</xref>&#x000a0;Moreover, the risk of thrombosis correlates strongly with LA due to beta2-glycoprotein I (beta2-GPI) autoantibodies than antiprothrombin autoantibodies.<xref ref-type="bibr" rid="article-24525.r6">[6]</xref><xref ref-type="bibr" rid="article-24525.r7">[7]</xref> These immunoglobins may develop spontaneously due to medications, infections, or as a consequence of autoimmune diseases such as lupus erythematosus.<xref ref-type="bibr" rid="article-24525.r8">[8]</xref>&#x000a0;Infections such as EBV, syphilis, and hepatitis C increase the likelihood of acquired lupus anticoagulant.</p>
      </sec>
      <sec id="article-24525.s3" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>Lupus anticoagulant is estimated to be present in 2 to 4% of the general population, but true prevalence is unclear. Estimates are that lupus anticoagulant is present in 15 to 34% of patients with systemic lupus erythematosus. LA Incidence increases with age and female sex.<xref ref-type="bibr" rid="article-24525.r9">[9]</xref>&#x000a0;Laboratory detection of LA is challenging due to the heterogenicity of antibodies and epitopes on protein in the phospholipids. Thus, there is no single LA test capable of detecting all LAs. Clinical laboratories have shown variance in sensitivity and specificity. There are many different mechanisms proposed for this variance, including adequate plasma preparation that is not platelet poor and dilutional effects of mixing studies that impact detection of LA.<bold>&#x000a0;</bold>Laboratory diagnosis of LA may be difficult but could allow for the optimal duration of therapy as the risk of occurrence and recurrence venous/arterial thromboembolism are high.<xref ref-type="bibr" rid="article-24525.r10">[10]</xref>&#x000a0;Initial positive testing for LA activity&#x000a0;should be repeated after at least 12 weeks to confirm its persistence as it could be falsely positive due to some drugs and infections.</p>
      </sec>
      <sec id="article-24525.s4" sec-type="Cellular Level&#x0000d;&#x0000a;">
        <title>Cellular Level
</title>
        <p>Lupus anticoagulants are predominantly IgG and IgM autoantibodies that bind to&#x000a0;negatively charged phospholipid-binding proteins, prothrombin, or beta2-glycoprotein I (beta2-GPI).<xref ref-type="bibr" rid="article-24525.r11">[11]</xref> Phospholipid-dependent coagulation is prolonged with LA; hence, the observed phenomenon in-vitro and ultimately leads to thrombus formation. There are many different mechanisms proposed for the induction of anti-phospholipid binding proteins, including infections, oxidative stress, and major stress such as surgery or trauma. Increasing evidence support the notion that oxidation unmasks critical antiphospholipid syndrome b-cell epitopes.<xref ref-type="bibr" rid="article-24525.r12">[12]</xref> All of these stressors combined help expose the phospholipids that eventually allows for antibodies to attach; this, in turn, leads to intravascular coagulation and thrombus formation.</p>
      </sec>
      <sec id="article-24525.s5" sec-type="Testing">
        <title>Testing</title>
        <p>There is no single test to detect lupus anticoagulant. However, a sequential nonstandard test exists that helps determine whether a patient has lupus anticoagulant.</p>
        <p>1) Initial testing, which is also called the screening test,&#x000a0;involves the use of one or more phospholipid-containing reagents. This test usually uses PTT, LA-sensitive PTT or dilute Russell viper venom test (DRVVT). These tests allow measuring the time it takes (in seconds) for a plasma sample to clot and which due to lupus anticoagulant gets prolonged beyond<bold>&#x000a0;</bold>the upper limit of the reference.</p>
        <p>2) Upon observation of prolongation in the above test, a mixing study is next. A mixing study is a mixture of an equal volume of patient&#x02019;s plasma with &#x0201c;normal&#x0201d; pooled plasma, and a PTT or preferably, DRVVT is performed on this mixture. Mixing study eliminates the possibility that prolongation is due to coagulation factor deficiency and confirms that an inhibitor is present. Mixing study also confirms that inhibitor is directed towards negatively charged phospholipid and not specific coagulation factor. The<bold>&#x000a0;</bold>mixing study fails to correct the prolonged coagulation test if it is due to LA.</p>
        <p>3) Additionally<bold>, </bold>a&#x000a0;confirmatory test involves the&#x000a0;addition of excess phospholipid to shorten or correct the prolonged coagulation test. Thus lupus anticoagulant is characterized by the correction of prolonged clotting time with added phospholipid and not with control plasma.&#x000a0;Many different sources of phospholipid are available, including aged platelets and synthetic phospholipids in the combination of APTT or DRVVT.</p>
        <p>The International Society of Thrombosis and Hemostasis (ISTH) states that four criteria must be met to confirm the presence of lupus anticoagulant.</p>
        <list list-type="order">
          <list-item>
            <p>(Screening test) Prolonged result in one of two coagulation tests that are phospholipids dependent such as PTT-LA or DRVVT</p>
          </list-item>
          <list-item>
            <p>(Mixing study) observe the prolonged result on mixing study</p>
          </list-item>
          <list-item>
            <p>(Confirmatory test)&#x000a0;Lack of prolonged time when adding additional phospholipids</p>
          </list-item>
          <list-item>
            <p>Ruling out other coexisting coagulation factor inhibitor such as factor VII.</p>
          </list-item>
        </list>
        <p>Lupus anticoagulant testing is often done simultaneously with cardiolipin antibody and anti-beta2-glycoprotein I antibodies when the antiphospholipid syndrome is suspected.<xref ref-type="bibr" rid="article-24525.r13">[13]</xref>&#x000a0;Despite current guidelines and recommendations, many issues remain including the lack of uniformity among laboratories with testing protocols and procedures that overall impact result interpretations. Integrated test that consists of only screening and the confirmatory test has been used to detect LA with convenience and less time consumption. However, further investigation into the accuracy of these tests is still needed.<xref ref-type="bibr" rid="article-24525.r14">[14]</xref>&#x000a0;In conclusion, LA diagnosis remains challenging and needs standardization.</p>
      </sec>
      <sec id="article-24525.s6" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Studies have shown lupus anticoagulant, compared to other antibodies, more strongly correlates with pregnancy morbidity and thrombosis.<xref ref-type="bibr" rid="article-24525.r15">[15]</xref> The presence of LA is suspected initially in a large number of cases, only due to an isolated prolongation of PTT. In such cases, followup is by the mixing study and the confirmatory test, as explained above. <xref ref-type="bibr" rid="article-24525.r16">[16]</xref> It is worth noting that while aCL and anti-beta2-GP I antibodies&#x000a0;are seldom affected by anticoagulation, LA activity could be&#x000a0;labeled falsely&#x000a0;positive&#x000a0;by anticoagulants such as warfarin, heparin, or newer anticoagulants including rivaroxaban, apixaban or dabigatran.<xref ref-type="bibr" rid="article-24525.r17">[17]</xref> The antiphospholipid syndrome&#x000a0;due to lupus anticoagulant should be further investigated and differentiated from other inherited and acquired thrombophilias as well.&#x000a0;The differential diagnosis for a patient with arterial or venous thrombus should be kept in mind which includes paroxysmal nocturnal hemoglobinuria, heparin-induced thrombocytopenia (HIT), myeloproliferative neoplasms, factor V Leiden mutation, protein C and S deficiency, thrombotic thrombocytopenia purpura, vasculitis hemolytic uremic syndrome and&#x000a0;disseminated intravascular coagulation.</p>
        <p>Once a patient has been diagnosed with LA causing antiphospholipid syndrome per the Sapporo criteria (also known as Sydney criteria ).<xref ref-type="bibr" rid="article-24525.r18">[18]</xref><xref ref-type="bibr" rid="article-24525.r19">[19]</xref> Treatment guidelines are similar to antiphospholipid syndrome caused by other implicated antibodies. The mainstay treatment for antiphospholipid syndrome, including lupus anticoagulant in patients with acute thromboembolism is anticoagulation. Warfarin is the mainstay treatment and recommended over direct oral anticoagulant (DOAC) for secondary prevention.<xref ref-type="bibr" rid="article-24525.r20">[20]</xref>&#x000a0;Since LA is associated with obstetric complications, heparin is recommended over warfarin during pregnancy.&#x000a0;</p>
      </sec>
      <sec id="article-24525.s7">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24525&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24525">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24525/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24525">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24525.s8">
        <title>References</title>
        <ref id="article-24525.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simanek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Panzer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lechner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pabinger</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Late spontaneous remissions in severe adult autoimmune thrombocytopenia.</article-title>
            <source>Ann Hematol</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>86</volume>
            <issue>10</issue>
            <fpage>705</fpage>
            <page-range>705-10</page-range>
            <pub-id pub-id-type="pmid">17503045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24525.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ay</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Posch</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gebhart</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Koder</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mackman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pabinger</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Thaler</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Low extracellular vesicle-associated tissue factor activity in patients with persistent lupus anticoagulant and a history of thrombosis.</article-title>
            <source>Ann Hematol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>98</volume>
            <issue>2</issue>
            <fpage>313</fpage>
            <page-range>313-319</page-range>
            <pub-id pub-id-type="pmid">30467688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24525.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jennings</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kitchen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Preston</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Greaves</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation.</article-title>
            <source>Thromb Haemost</source>
            <year>1997</year>
            <month>May</month>
            <volume>77</volume>
            <issue>5</issue>
            <fpage>934</fpage>
            <page-range>934-7</page-range>
            <pub-id pub-id-type="pmid">9184405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24525.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripodi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Laboratory testing for lupus anticoagulants: a review of issues affecting results.</article-title>
            <source>Clin Chem</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>53</volume>
            <issue>9</issue>
            <fpage>1629</fpage>
            <page-range>1629-35</page-range>
            <pub-id pub-id-type="pmid">17712001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24525.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Galli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luciani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bertolini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barbui</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature.</article-title>
            <source>Blood</source>
            <year>2003</year>
            <month>Mar</month>
            <day>01</day>
            <volume>101</volume>
            <issue>5</issue>
            <fpage>1827</fpage>
            <page-range>1827-32</page-range>
            <pub-id pub-id-type="pmid">12393574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24525.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Laat</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Derksen</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Urbanus</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Roest</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de Groot</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome.</article-title>
            <source>Blood</source>
            <year>2004</year>
            <month>Dec</month>
            <day>01</day>
            <volume>104</volume>
            <issue>12</issue>
            <fpage>3598</fpage>
            <page-range>3598-602</page-range>
            <pub-id pub-id-type="pmid">15315975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24525.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devreese</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Peerlinck</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hoylaerts</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants.</article-title>
            <source>Blood</source>
            <year>2010</year>
            <month>Jan</month>
            <day>28</day>
            <volume>115</volume>
            <issue>4</issue>
            <fpage>870</fpage>
            <page-range>870-8</page-range>
            <pub-id pub-id-type="pmid">19965629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24525.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Favaloro</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Mohammed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Curnow</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pasalic</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives.</article-title>
            <source>Pathology</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>51</volume>
            <issue>3</issue>
            <fpage>292</fpage>
            <page-range>292-300</page-range>
            <pub-id pub-id-type="pmid">30665674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24525.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Love</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance.</article-title>
            <source>Ann Intern Med</source>
            <year>1990</year>
            <month>May</month>
            <day>01</day>
            <volume>112</volume>
            <issue>9</issue>
            <fpage>682</fpage>
            <page-range>682-98</page-range>
            <pub-id pub-id-type="pmid">2110431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24525.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dembitzer</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Ledford Kraemer</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Meijer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Peerschke</surname>
                <given-names>EI</given-names>
              </name>
            </person-group>
            <article-title>Lupus anticoagulant testing: performance and practices by north american clinical laboratories.</article-title>
            <source>Am J Clin Pathol</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>134</volume>
            <issue>5</issue>
            <fpage>764</fpage>
            <page-range>764-73</page-range>
            <pub-id pub-id-type="pmid">20959659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24525.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnout</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants.</article-title>
            <source>Thromb Haemost</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>86</volume>
            <issue>1</issue>
            <fpage>83</fpage>
            <page-range>83-91</page-range>
            <pub-id pub-id-type="pmid">11487046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24525.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Passam</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Rahgozar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Raftery</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ioannou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Gemmell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Giannakopoulos</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Hogg</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Krilis</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Beta 2 glycoprotein I is a substrate of thiol oxidoreductases.</article-title>
            <source>Blood</source>
            <year>2010</year>
            <month>Sep</month>
            <day>16</day>
            <volume>116</volume>
            <issue>11</issue>
            <fpage>1995</fpage>
            <page-range>1995-7</page-range>
            <pub-id pub-id-type="pmid">20847215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24525.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bertolaccini</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Amengual</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Andreoli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Atsumi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chighizola</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Forastiero</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Groot</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lakos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meroni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ortel</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Petri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roubey</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sciascia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tebo</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Tincani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Willis</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends.</article-title>
            <source>Autoimmun Rev</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>917</fpage>
            <page-range>917-30</page-range>
            <pub-id pub-id-type="pmid">24824074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24525.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobsen</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Barna-Cler</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Triplett</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Wisl&#x000f8;ff</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The Lupus Ratio test--an interlaboratory study on the detection of Lupus anticoagulants by an APTT-based, integrated, and semi-quantitative test. Fifth International Survey of Lupus Anticoagulants--ISLA 5.</article-title>
            <source>Thromb Haemost</source>
            <year>2000</year>
            <month>May</month>
            <volume>83</volume>
            <issue>5</issue>
            <fpage>704</fpage>
            <page-range>704-8</page-range>
            <pub-id pub-id-type="pmid">10823266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24525.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Urbanus</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Siegerink</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Roest</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosendaal</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>de Groot</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Algra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study.</article-title>
            <source>Lancet Neurol</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>8</volume>
            <issue>11</issue>
            <fpage>998</fpage>
            <page-range>998-1005</page-range>
            <pub-id pub-id-type="pmid">19783216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24525.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pengo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tripodi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reber</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rand</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Ortel</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Galli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Groot</surname>
                <given-names>PG</given-names>
              </name>
              <collab>Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis</collab>
            </person-group>
            <article-title>Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.</article-title>
            <source>J Thromb Haemost</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>7</volume>
            <issue>10</issue>
            <fpage>1737</fpage>
            <page-range>1737-40</page-range>
            <pub-id pub-id-type="pmid">19624461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24525.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripodi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>To mix or not to mix in lupus anticoagulant testing? That is the question.</article-title>
            <source>Semin Thromb Hemost</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>385</fpage>
            <page-range>385-9</page-range>
            <pub-id pub-id-type="pmid">22618530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24525.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bobba</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>A review of the sapporo and revised Sapporo criteria for the classification of antiphospholipid syndrome. Where do the revised sapporo criteria add value?</article-title>
            <source>J Rheumatol</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>34</volume>
            <issue>7</issue>
            <fpage>1522</fpage>
            <page-range>1522-7</page-range>
            <pub-id pub-id-type="pmid">17552042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24525.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miyakis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lockshin</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Atsumi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Branch</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Brey</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Cervera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Derksen</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>DE Groot</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Koike</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Meroni</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Reber</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shoenfeld</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tincani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vlachoyiannopoulos</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Krilis</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).</article-title>
            <source>J Thromb Haemost</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>295</fpage>
            <page-range>295-306</page-range>
            <pub-id pub-id-type="pmid">16420554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24525.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arachchillage</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Efthymiou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mackie</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Lawrie</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Machin</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism.</article-title>
            <source>Thromb Res</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>135</volume>
            <issue>2</issue>
            <fpage>388</fpage>
            <page-range>388-93</page-range>
            <pub-id pub-id-type="pmid">25555316</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
